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Abstract
Bronchopulmonary dysplasia (BPD) is the most common complication in preterm infants and often complicated by pulmonary
hypertension (PH), leading to substantial morbidity and mortality. Sildenafil is often used to treat PH and improve symptoms in this
condition, even though evidence of safety and effectiveness is scarce. The aim of this study was to perform a systematic review and
meta-analysis about the effectiveness and safety of chronic use of sildenafil in preterm infants with BPD-associated PH. Data
sources were PubMed, EMBASE, and Medline. Studies reporting the effectiveness of sildenafil therapy in BPD-associated PH in
newborns and infants were included. All-cause mortality, improvement in PH, improvement in respiratory scores, and adverse
events were extracted. Five studies were included, yielding a total of 101 patients with 94.2 patient-years of total follow-up. The
pooled mortality rate was 29.7%/year (95% confidence interval [CI]¼ 6.8–52.7). Estimated pulmonary arterial pressure
improved> 20% in 69.3% (95% CI¼ 56.8–81.8) of patients within 1–6 months. Respiratory scores improved in 15.0% (95%
CI¼ 0.0–30.4) of patients within 2–7 days. There were no serious adverse events during sildenafil therapy. This systematic
review shows that in the treatment of BPD-associated PH in preterm infants, sildenafil may be associated with improvement in
PAP and respiratory scores. However, there is no clear evidence of its effect on mortality rates. Considering BPD as a complex
disease with variable expression patterns, these results support the need for a prospective registry and standardized approach.
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Introduction
Bronchopulmonary dysplasia (BPD) is the most common
complication in preterm infants and is associated with
adverse short-term and long-term outcomes.1 Twenty-
seven percent of infants born at 28 weeks of gestational
age will develop BPD and this incidence is still increasing,
due the growing number of preterm infants surviving
birth.2–5 BPD can be categorized according to severity.1,6
Pulmonary hypertension (PH) is a frequently occurring
complication in infants with BPD, with a reported incidence
in the range of 18–37%.7–10 This condition is associated with
a high mortality rate, in the range of 20–38% within two
years.11–13
PH is a symptom of various forms of pulmonary vascular
diseases and can be categorized into ﬁve groups based on
clinical course and underlying disease according to the
World Health Organization (WHO) classiﬁcation.14
Many new drugs have been developed to treat patients
with PH in group 1 (pulmonary arterial hypertension
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[PAH]).15,16 Sildenaﬁl is one of the drugs inﬂuencing the
nitric oxide-pathway, which, together with the prostacyclin
pathway and endothelin receptors, are three main targets for
intervention in PAH.15,16 Sildenaﬁl inhibits the enzyme
phosphodiesterase-5A (PDE-5A), enhancing the availability
of cyclic guanosine monophosphate (cGMP), which leads to
vasodilatation and smooth-muscle growth inhibition.17
Chronic treatment with sildenaﬁl has been shown to be
eﬀective in PAH and is one of the most important oral
drugs for PAH nowadays.18 BPD-associated PH, categor-
ized in group 3 (PH due to lung diseases), is very diﬀerent in
etiology and vascular morphology compared with PAH.
Nevertheless, many clinicians nowadays frequently apply
treatment strategies developed for group 1 to other forms
of PH, for example in the treatment of BPD-associated
PH.19 However, studies on the eﬀectiveness of sildenaﬁl in
the treatment of BPD-associated PH in preterm infants are
scarce, often small in sample size and an overview of
reported outcome is lacking. In addition, there has been
an oﬃcial warning from the Food and Drug
Administration (FDA) on the use of sildenaﬁl in children
aged 1–17 years, especially when using higher doses.20 The
aim of this study was to perform a systematic review and
meta-analysis of reported eﬀectiveness and safety of chronic
use of sildenaﬁl in preterm infants with BPD-associated PH.
Methods
Search strategy and selection of studies
This systematic review was conducted according to the
PRISMA statement for systematic reviews.21 On January
14, 2018, the EMBASE, Medline, Ovid, and Cochrane data-
bases were searched by a biomedical information specialist
(supplement). The search was limited to studies that were
written in English. After extracting duplicates, the remain-
ing publications were reviewed by two independent
reviewers (MG and LR) to assess the relevance of
each study.
Studies were considered relevant if the study was an ori-
ginal study reporting mortality after sildenaﬁl therapy for
BPD-associated PH in infants. Studies only describing a
mixed population including patients with other chronic
lung diseases besides BPD, without reporting BPD-speciﬁc
mortality rates separately, were excluded. Case reports, case
series, and conference abstracts were also excluded. In case
of overlapping study populations, only the most recent or
most complete study was included. When a disagreement
occurred between the reviewers, an agreement was nego-
tiated with a third reviewer (BB). The references of included
articles were screened for relevant studies.
BPD was deﬁned according to the current National
Institutes of Health deﬁnition.6,22 According to the guide-
lines, PH was deﬁned as a mean pulmonary artery blood
pressure (mPAP) 25mmHg at rest, as measured by cardiac
catheterization.23,24 Because of the invasiveness of cardiac
catheterization and its subsequently less frequent use in
pediatric practice, the peak tricuspid regurgitation jet vel-
ocity (TRJV) measured by echocardiography was also
accepted as an estimate of PH.24,25 The following surrogate
parameters using echocardiography were also considered as
conﬁrmation of the diagnosis: TRJV 2.8m/s; systolic ﬂat-
tening of the bowed interventricular septum; estimated
PAP/systolic blood pressure ratio of >0.5 or time to peak
velocity to right ventricular ejection time ratio <0.35.26
Data extraction
Data of each study were extracted independently by two
reviewers (MG, LR), using Microsoft Oﬃce Excel 2010
(Microsoft Corp., Redmond, WA, USA, version
14.0.7177.5000). In case of disagreements between the
reviewers, an agreement was negotiated. The following
study and baseline patient characteristics were collected:
year of publication; study design; the number of included
patients; the inclusion period; the duration of the follow-up;
the gestational age at birth; co-medication for BPD and PH;
the postnatal age at the start of sildenaﬁl treatment; dur-
ation of sildenaﬁl treatment; and the initial, maximum, and
median sildenaﬁl dose.
The primary outcome parameter was all-cause mortality.
Secondary outcome parameters were: improvement in PH;
respiratory improvement; and adverse events (AE).
Improvement in PH was deﬁned as a decrease of 20% in
right ventricular (RV) systolic pressure or TRJV gradient,
improvement of interventricular septum ﬂattening (1) or
reduction of PAP as measured by cardiac catheterization.27
Respiratory improvement was deﬁned as a decrease of
20% in requirement of inspired oxygen fraction or a
decrease in the respiratory severity score (calculated as
mean airway pressure x FiO2).
28
Statistical analyses
Baseline patient characteristics were pooled with the use of
sample size weighting. In case data were reported in med-
ians, the median was used as an approximation of the mean.
If the SD was not available, the range was divided by 4, or
the interquartile range by 1.35, as an approximation of the
SD. Linearized occurrence rates of outcome measures were
pooled with the use of inverse variance weighting according
to the number of patient-years of total follow-up, when the
deﬁnition of outcome parameters was comparable across
studies. If the total follow-up duration (in patient-years)
was not reported, it was calculated by multiplying the
number of patients with the mean follow-up of that study.
When the number of studies was large enough (3 studies)
to estimate the between-study variance (Tau2), a random
eﬀects model was used, otherwise a ﬁxed eﬀects model was
used. Outcomes were pooled on a linear (non-logarithmic)
scale as the Shapiro–Wilk test showed no evidence of skew-
ness among the included studies in any of the outcome
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measures. A P value of <0.05 was considered statistically
signiﬁcant. Heterogeneity among the studies was analyzed
with the Cochran Q statistic and the I2 index. Publication
bias was assessed with use of funnel plots. The authors take
full responsibility for the integrity of the data.
Results
The search identiﬁed 370 unique publications of which 13
were included for full-text screening and 5 were included in
this systematic review (Fig. 1).29–33 This yielded a total of
101 patients with 94.2 patient-years of total follow-up
(pooled mean follow-up 1.0 year) (Table 1). All studies
were retrospective in design. Table 1 gives an overview of
study and baseline patient characteristics. The pooled mean
gestational age at birth was 26.3 2.7 weeks and the post-
natal age at start of sildenaﬁl therapy was 21.9 15.9 weeks.
Initial sildenaﬁl dose was in the range of 0.3–1.5mg/kg/day,
with a maximum dose of 6.0–8.0mg/kg/day.
All included studies followed the guidelines for the diag-
nosis of BPD. Since not all patients underwent cardiac cath-
eterization to conﬁrm the diagnosis of PH, we also used the
surrogate parameters assessed by echocardiography (see
‘‘Methods’’). Initial mPAPs were in the range of
27–42mmHg and systolic RV pressures in the range of
38–100mmHg.29,31,32 One study assessed pulmonary vascu-
lar resistance (PVR) by cardiac catheterization in a subset of
patients, in the range of 2.3–9.2 WU.29
The majority of patients also received other medication
besides sildenaﬁl during follow-up. This included systemic
(10.7%) or inhaled (21.4%) steroids, milrinone (11.1%), or
other PH-medication such as bosentan (10.3%), and inhaled
nitric oxide (iNO) (54.9%) (Table 2).
Study outcomes
The pooled mortality rate during a mean follow-up of 1.0
year was 29.7%/year (95% conﬁdence interval [CI]¼ 6.8–
52.7%/year).29–33 The cause of death was speciﬁed in ﬁfteen
patients from four studies: 12/15 died due to ‘‘respiratory
failure in BPD-PH’’, 2/15 patients due to sepsis, and 1/15
due to neurological injury.29–32. Estimated PAP improved
in 69.3% (95% CI¼ 56.8–81.8%) of patients within 1–6
months.31–33 One study reported changes in PAPs as
measured by echocardiography (56.5 10.4 to 34.3
8.3mmHg).32 Respiratory scores (FiO2 and RSS) improved
in 15.0% (95% CI¼ 0.0–30.4%) of patients within 2–7 days
(Table 3).31–33 Pooled respiratory scores and estimates of
PAP could not be assessed in 2/5 studies, due to the fact
that these outcome parameters were not reported separately
Fig. 1. Flowchart of study selection, based upon PRISMA statement for systematic reviews.21
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for BPD-associated PH patients treated with sildenaﬁl.29,30
All studies assessed possible AEs during sildenaﬁl treat-
ment. There were no serious AEs. AEs were all minor and
included transient hypotension (11.8%), hypotension need-
ing temporary cessation (3.0%), and frequent erections
(1.0%).29–33 Publication bias could not be assessed due to
the limited number of studies.
Discussion
This systematic review shows that in the treatment of BPD-
associated PH in preterm infants, sildenaﬁl is associated
with reduction in PAP and improvements in respiratory
score. However, there is no clear evidence of its eﬀect on
mortality rates. No serious AEs were reported. The results
of this study raise the question: Is chronic use of sildenaﬁl
eﬀective as a treatment for BPD-associated PH?
Recent experimental research has shown a positive eﬀect
of sildenaﬁl in the prevention of PH in neonatal rats with
BPD. Administration of sildenaﬁl in this model alleviated
the development of lung injury, due to improvement of
alveolarization and recovery of the pulmonary angiogen-
esis.35,36 In addition, sildenaﬁl may enhance RV function,
as has been demonstrated in experimental studies.37 These
data suggest that preterm infants with BPD at risk for PH
may beneﬁt from preventive sildenaﬁl therapy. Our results
show that sildenaﬁl appears to be associated with improve-
ments in estimates of PAP and respiratory scores; however,
sildenaﬁl showed no eﬀect on mortality rates. Prior publi-
cations have reported mortality rates of 20–36% in infants
with BPD-associated PH without sildenaﬁl therapy.9,10,12
There may be several reasons for the discrepant results
between changes in estimates of PVR and mortality in this
systematic review.
Although the studies reported in this systematic review
have added important information to the clinicians, this
analysis also indicates some weaknesses that should be
taken into account. First, it should be noted that various
evaluation methods were used to diagnose PH. The formal
deﬁnition is a mPAP> 25mmHg. Unfortunately, only one
study measured PAPs invasively, the others inferred PAPs
from echocardiographic indices as TRJV or septal ﬂatten-
ing. Second, clinical eﬀects of a drug, or the lack thereof,
should be evaluated in combination with the eﬀective drug
dosage. There is no information available regarding the
dose-eﬀect relation in the use of sildenaﬁl for treatment of
BPD-associated PH. Most institutions gradually increase
the dosage to avoid side eﬀects as systemic hypotension.
Confusion may arise from the fact that low-dose sildenaﬁl
has been shown to improve ventilation-perfusion leading to
a reduction on RSS, whereas higher dosages are needed to
aﬀect pulmonary vascular remodeling. Indeed, the study
performed by Trottier-Boucher et al. reported that improve-
ment in RSS was achieved after 48 h, but echocardio-
graphic-derived reduction in PAP only after 19 days. This
dose-dependent and hence time-dependent eﬀect of
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sildenaﬁl on clinical improvement should be incorporated in
prospective registries. Also, careful assessment of potential
pulmonary vein stenosis is necessary when evaluating the
eﬀect of sildenaﬁl.11
In addition, although PH does increase the risk of mor-
tality in BPD, it is not the only contributor.10 Mortality
among infants with BPD is inﬂuenced by multiple factors,
such as prematurity and associated co-morbidities. One
factor relating to outcome not analyzed in any of these
studies is the reduction in lung volume associated with pre-
maturity. The changes in the pulmonary vasculature in
BPD, categorized in group 3 according to the classiﬁcation
of the WHO, may diﬀer from those in PAH, categorized in
group 1. Sildenaﬁl has been tested in children with PAH in a
randomized controlled trial in which start of therapy and
the follow-up were standardized.38 Unfortunately, the diag-
nosis of PH, timing of intervention, dosing, and follow-up
have not been standardized in infants with BPD.
Consequently, there may have been selection bias due to
the lack of a standardized approach, leading to an overre-
presentation of more severe cases.
The gold standard for evaluation of PH is measurement
of PAP by cardiac catheterization.39 However, clinicians
hesitate to perform cardiac catheterization in preterm
infants with pulmonary disease due to its invasiveness,
need for intubation, and reported adverse eﬀects.40 Still,
the recommendation is that cardiac catheterization should
be performed before the initiation of PAH-targeted therapy,
such as sildenaﬁl. A prerequisite for a prospective study or
registry is a proper deﬁnition and standardized diagnostic
approach. Fortunately, many centers can nowadays perform
invasive measurements with sedation rather than intubation
and general anesthesia. The hemodynamic evaluation
should include the assessment of ratio of PA and SA pres-
sure and, if possible, resistances. While echocardiography is
widely used, there is no consensus in the literature about the
usefulness of echocardiography in the follow-up of
PH.34,41,42 The sensitivity of echocardiography to assess
PH is suboptimal, due to the requirement of tricuspid
valve regurgitation to observe signs of PH. A recent study
proposed guidelines for detection of PH in infants with
BPD that recommends a staged approach using
Table 3. Pooled estimates of the outcome parameters.
Study
Mean follow-up
duration (months)
Mortality
rate (%/year)
Improvement in
the estimate of the PAP (%)
Improvement in
respiratory scores (%)
Mourani et al.30 7.9 7.6 25.2 NR NR
Nyp et al.31 12.0 2.9 19.0 70.0 14.3*y,z
Tan et al.32 9.0 3.0 36.2 66.7 0.0§y
Trottier-Boucher et al.33 5.6 2.4 74.3 71.4 34.8§yz
Kadmon et al.29 24.0 15.6 2.9 NR NR
Pooled effect (95% CI) 11.2 7.5 27.6 (12.6–60.4)** 69.3 (56.8–81.8)yy 15.0 (0.0–30.4)**
I2 80.6 0.0 58.2
X2 P value <0.001 0.9 0.05
*Improvement within 48 h.
yUsing FiO2 measurements.
zUsing RSS.
§Improvement within 168 h.
**Using random effects model.
yyFixed effect model.
NR, variable not reported; PAP, pulmonary arterial pressure.
Table 2. Medication used concomitantly during sildenafil therapy.
Exogenous iNO (%) Milrinone (%) Bosentan (%) Systemic steroids (%) Inhaled steroids (%)
Mourani et al.30 72.0 16.0 8.0 0.0 0.0
Nyp et al.31 52.4 19.0 0.0 42.9 47.6
Tan et al.32 4.5 NR 0.0 0.0 0.0
Trottier-Boucher et al.33 91.3 0.0 17.4 0.0 34.8
Kadmon et al.29 NR NR 29.4 NR NR
Pooled total 54.9 11.1 10.3 10.7 21.4
NR, variable not reported.
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echocardiography as a screening tool for PH and subse-
quently cardiac catheterization before initiating treatment
with long-term medication to conﬁrm the diagnosis and to
assess severity and potential contributing factors.43 The
interpretation of the data in this review was hampered by
diﬀerent echocardiographic techniques to assess the PAP in
preterm infants with BPD. Only one study assessed PVR
using cardiac catheterization at baseline in a subset of
patients.29 PVR in this study was in the range of 2.3–9.2
WU, suggesting that not all patients fulﬁlled the PH criteria.
These data call for a prospective registration and standar-
dized diagnostic and therapeutic approach for patients with
BPD-associated PH.
Should we design a prospective randomized trial to investi-
gate the eﬀectiveness of sildenaﬁl in the treatment of PH in
BPD? Suppose we aim for an absolute reduction in mortality
of 15% within one year, assuming an estimated mortality of
25% in the control group, a total of 214 patients with BPD-
associated PH would be required to detect this diﬀerence with
80% power at a 0.05 signiﬁcance level with a 1:1 sampling ratio.
This might be feasible in a large multicenter study at a consid-
erable cost. Yet, given the complexity of the origin of BPD-
associated PH, it is doubtful whether mono-therapy with silde-
naﬁl, or any other PAH-targeting therapy, will lead to suﬃcient
clinical eﬀects. Recent experience with treatment of adult
patients with PH advocate the start of dual or even triple ther-
apy at time of diagnosis.44 Another complicating issue in pedi-
atric trial design is the deﬁnition of a proper endpoint. In this
respect, mortality, a frequently reached endpoint in BPD-asso-
ciated PH may be a relevant endpoint. Secondary endpoints
could be quality of life as reﬂected in RSS scores and oxygen
dependency. These practical aspects may further complicate the
design of a proper pediatric trial. An alternative strategy may be
a prospective cohort including diagnostic criteria and standar-
dized follow-up, observing both short-term and long-term out-
comes, based on recent research and guidelines.45–49
Strengths and limitations
This systematic review and meta-analysis is the ﬁrst to
review the eﬀectiveness and safety of sildenaﬁl in infants
with BPD-associated PH and encompasses the largest
number of patients so far. All included studies were retro-
spective and observational in design and had no standard-
ization of patient inclusion, treatment, and follow-up. As
such, the inherent limitations of meta-analyses of retrospect-
ive observational studies should be taken into consideration.
The retrospective nature of the studies precludes interpret-
ation on the eﬀects of co-medication. One study reported
that in some cases co-medication for PAH was started when
the use of sildenaﬁl did not improve PH.30 These data sug-
gest that the eﬀect of sildenaﬁl might has been overesti-
mated. Selection bias could have inﬂuenced our results,
because case reports, case series, and unpublished data
were not included. The limited number of studies precluded
assessment of publication bias.
Conclusion
BPD-associated PH is a complex disease with variable
expression patterns. This systematic review shows that in
the treatment of BPD-associated PH in preterm infants,
sildenaﬁl may be associated with improvement in PAP and
respiratory scores. However, there is no clear evidence of its
eﬀect on mortality rates. These results support the need for a
prospective registration and standardized approach, includ-
ing entry criteria, to allow optimization for the child with
BPD-associated PH.
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